Globus Medical, Inc. $GMED Shares Sold by Inceptionr LLC

Posted by on Jul 29th, 2026

Inceptionr LLC reduced its stake in Globus Medical, Inc. (NYSE:GMED – Free Report) by 70.0% during the 1st quarter, HoldingsChannel reports. The firm owned 2,761 shares of the medical device company’s stock after selling 6,449 shares during the period. Inceptionr LLC’s holdings in Globus Medical were worth $238,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Advisory Services Network LLC acquired a new position in Globus Medical in the 3rd quarter valued at $26,000. EverSource Wealth Advisors LLC raised its position in Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in shares of Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares during the period. Parallel Advisors LLC lifted its stake in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares during the period. Finally, Headlands Technologies LLC boosted its holdings in shares of Globus Medical by 485.4% in the second quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock valued at $45,000 after acquiring an additional 631 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Transactions at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 18.38% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on GMED. Piper Sandler reduced their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. Royal Bank Of Canada dropped their target price on Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Stifel Nicolaus cut their target price on Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research note on Wednesday, July 8th. Needham & Company LLC raised their price target on Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Truist Financial decreased their price target on Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Globus Medical presently has a consensus rating of “Moderate Buy” and an average target price of $102.08.

Read Our Latest Stock Report on Globus Medical

Globus Medical Trading Up 2.9%

GMED stock opened at $80.49 on Wednesday. The company has a market cap of $10.93 billion, a P/E ratio of 18.72, a P/E/G ratio of 1.62 and a beta of 0.95. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40. The company’s 50-day moving average price is $79.79 and its 200 day moving average price is $85.85.

Globus Medical (NYSE:GMED – Get Free Report) last issued its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.20. The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts expect that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

About Globus Medical

(Free Report)

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

Featured Stories

Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.